| Improve outcomes of children with cancer and haematological disorders |
INPHOG Research foundation & Dept of Medical Oncology, SRCC |
2022 |
3 years |
| Counselling and hand holding services to cancer patients |
Sanjeevni Life Beyond Cancer, Gold Mohur, Princess Street, Mumbai & Dept of Medical oncology, SRCC |
2021 |
5 years |
| Collaboration on CPR Training |
Indian Academy of Pediatrics Business Bay, 5th floor, Plot no 51, sector I, Juhinagar, Nerul, Navi Mumbai & Dept of Pediatrics, MGMCH |
2020 |
5 years |
| Bone Marrow Transplant Program |
South East Asia Institute of Thalassemia Ashram Marg, Durgapura Bypass, Jawahar Circle, Jaipur & Dept of Pediatrics & Dept of Medicine MGMCH |
2021 |
2 years |
| Corporate Lab Services |
Metropolis Health Care Pvt. Ltd., 250 Udyog Bhavan Mumbai & Central Lab, MGMCH |
2022 |
Open ended |
| Corporate Lab Services |
S N Gene Lab, 2nd Floor RTO Circle Ring Road Surat & Central Lab, MGMCH |
2022 |
5 Years |
| Corporate Lab Services |
Santokba Durlabhji Memorial Hospital Cum Medical Research Institute, Jaipur. |
2022 |
5 Years |
| Corporate Lab Services |
OK Diagnostic Centre Scheme Jaipur & Central Lab, MGMCH |
2022 |
5 Years |
| Academic Training |
Apna Ghar Ashram, Jaipur & Mahatma Gandhi Physiotherapy College |
2022 |
Open ended |
| Collaboration on Promotion |
Rajasthan chartered association of physiotherapy & Mahatma Gandhi Physiotherapy College |
2021 |
5 years |
| Collaboration on research, curriculum development, industrial training and placement with student and faculty exchange |
Janardhan Rai Nagar Rajasthan Vidyapeeth, Udaipur & Mahatma Gandhi Physiotherapy College |
2022 |
5 years |
| Academic Training |
Mentally retarded and child welfare rehabilitation Jamdoli & Mahatma Gandhi Physiotherapy College |
2022 |
Open ended |
| Capacity building and strengthening of Hospital Infection Control |
CDC AIIMS Delhi & Dept of Critical Care Medicine |
2022 |
Open ended |
| Academic collaboration |
DMC Ludhiana & Dept of Critical care, MGUMST |
2022 |
Open ended |
| Academic collaboration |
Tata Memorial Hospital Mumbai & Dept of Critical care, MGUMST |
2022 |
Open ended |
| Academic collaboration |
Liberation Study Research Japan & Dept of Critical care, MGUMST |
2022 |
Open ended |
| Academic collaboration |
Max Hospital, Delhi & Dept of Critical care, MGUMST |
2022 |
Open ended |
| Collaboration on research with student and faculty exchange |
Manipal university Jaipur-Ajmer Express Highway, Dehmi Kalan, Near GVK Toll Plaza, Jaipur, Rajasthan & MGUMST |
2021 |
5 years |
| Collaboration on Research |
Sibar Institute of Dental Sciences & MGDCH |
2021 |
5 years |
| Collaboration on Road Safety |
Sahayata NGO, Taru Chaya Nagar, Jaipur & MGUMST |
2022 |
3 years |
| Collaboration for Student Internship |
Saint Johns Research Institute, Bangalore Karnataka & Mahatma Gandhi Institute of Health Informatics |
2022 |
2 years |
| Collaboration for e Hospital Training |
King George Medical University, Lucknow, U.P.& Mahatma Gandhi Institute of Health Informatics |
2022 |
2 years |
| Collaboration on Faculty and student skill development program |
PHI India, Jaipur, Raj & Mahatma Gandhi Institute of Health Informatics |
2024 |
1 year |
| Collaboration in areas of clinical research |
Birla Institute of Scientific Research Statue Circle, Jaipur, Rajasthan & MGUMST |
2021 |
5 years |
| Collaboration for training and academic exchange in health informatics |
MUHS Nashik & MGIAHS |
2024 |
Open ended |
| Collaboration for training, research & academic exchange |
Consortium of Accredited Healthcare Organisation (CAHO) & MGCOHA |
2024 |
5 years |
| Establishing centre of excellence for science of happiness |
Rekhi Foundation & MGUMST |
2024 |
Open ended |
| Hospital based cancer registry |
ICMR & SRCC |
2024 |
2027 |
| Collaboration for training, research, clinical referrals & academic exchange |
Rehab Buddy child development & autism institute & Clinical Nutrition & Dietetics, MGUMST |
2024 |
2026 |
| Collaboration for research, clinical knowledge |
Sharda School of allied health sciences |
2024 |
2 years |
| Expansion of courses at MGUMST |
Rising Rajasthan, Govt of Rajasthan |
2024 |
2-5 years |
| Research |
Sultan Qaboos University, Oman |
2024 |
3years |
| Clinical trial with Astrazeneca Private Limited |
A Phase III, Open-label, Randomised Study of Datopotamab, Deruxtecan (Dato-DXd) Versus Investigator's Choice of Single-Agent Chemotherapy in Patients who are not candidates for PD 1/PD Li Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION Breast02) |
2022 |
Open ended |
| Clinical trial with Astrazeneca Private Limited |
A Phase III, Randomized, Open-label, with Tremelimumab + Lenvatinib Given Concurrently with Transarterial Chemoembolization (TACE) Compared to TACE Alone in Patients with Locoregional Hepatocellular Carcinoma (EMERALD-3) |
2022 |
Open ended |
| Clinical trial with Raptim Research Pvt. Ltd. |
A Phase 2, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial Comparing Chemoimmunotherapy (Paclitaxel-Carboplatin -Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) as Neoadjuvant Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma. |
2023 |
Open ended |
| Clinical trial with PSI CRO pharma India Pvt Ltd |
Phase 3, Open-Label, Randomized study comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy. VIKTORIA-1 |
2023 |
Open ended |
| Clinical trial with Astrazeneca Private Limited |
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-Small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8) |
2022 |
Open ended |
| Clinical trial with PSI CRO pharma India Pvt Ltd |
A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s Choice in Patient with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia ( platelet counts <50,000/ µL) |
2024 |
Open ended |
| Clinical trial with Fortrea Development India Private Limited |
Phase III, randomised study of Camizestrant (AZD9833, a Next-Generation, Oral Selective EstrogenReceptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or
High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease. (Cambria-2) |
2024 |
Open ended |
| Clinical trial with Alkem Laboratories Pvt Ltd |
A Prospective, Randomized, Multicenter, Comparative, Double-blind, Parallel study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Biosimilar Pertuzumab (ENZENE) with Reference Pertuzumab (Perjeta®, Genentech Inc.,) in Previously Untreated Patients with HER2 Positive Metastatic Breast Cancer. |
2024 |
Open ended |
| Clinical trial with Astrazeneca Private Limited |
A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) |
2024 |
Open ended |
| Clinical trial |
A randomized, double-blind, multi-centre, active-control, parallel group study to compare efficacy, safety, immunogenicity and pharmacokinetics of Lupin’s Nivolumab (LUBT022) with Innovator’s Nivolumab in patients with locally advanced or metastatic non-small cell lung cancer. |
2025 |
Open ended |
| Clinical trial |
Phase 2, Open-Label, Randomized Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Evixapodlin Administered as 2nd Line Monotherapy in Subjects with Advanced Non-Small Cell Lung Cancer Expressing PD-L1 |
2025 |
Open ended |
| Clinical trial with St. Johns Research Institute |
Radical PC: RADICAL PC1 is a prospective cohort study of men with a new diagnosis of prostate cancer RADICAL PC2 is a randomized, controlled trial of a systematic approach to modifying cardiovascular and lifestyle risk factors in men with a new diagnosis of prostate cancer |
2024 |
Open ended |
| Screening study |
FIGHT HPV- Impact of an educational intervention on HPV knowledge and attitudes towards HPV and its vaccines among adolescent school girls |
2024 |
Open ended |
| Screening study |
Tobacco Awareness, Cessation and Oral Screening (TACOS) for factory workers in Bhawani Mandi , District Jhalawar (Rajasthan, India) |
2024 |
Open ended |
| Clinical trial with Astrazeneca Private Limited |
A Phase III, Randomized, Open-Label, Multi-Centre, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent
Chemoradiotherapy (eVOLVE-HNSCC) |
2024 |
Open ended |
| Collaboration for training, research & academic, student & faculty exchange |
University of Peradeniya, Sri Lanka |
2025 |
5 years |
| Integrating healthcare in to education ecosystem |
Poornima College of Engineering |
2025 |
5 years |
| Collaboration for training, research & academic, student & faculty exchange |
CRC Jamdoli |
2025 |
2 years |
| Cooperation in research, teaching and extension activities |
Hasselt University, Belgium |
2025 |
3 years |
| Training, Research, student exchange, IPR |
ERASMUS project
Asian Association of Transfusion Medicine (AATM) |
2025 |
5 years |